Skip to main content

Table 4 Univariate analyses of the associations between FGFR polymorphisms and the response of neoadjuvant chemotherapy

From: Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients

Target Gene Polymorphisms/Genotype Nonresponders
N = 29(32%)
Responders
N = 61(68%)
OR (95% CI) P P HWE
FGFR1 rs2288696      0.014
  C/C 25(86.2) 50(82.0) Reference 1.000  
  C/T 1(3.4) 11(18.0) 1.00 (0.28–3.64) 0.999  
  T/T 3(10.3) 0(0) 0 0.615  
  Dominat model 4(13.8) 4(6.6) 0.73(0.21–2.52)   
  Recessive model 26(89.7) 61(100) 0 1.000  
  Alleles      
  C 51(87.9) 111(91.0) Reference 0.344  
  T 7(12.1) 11(9.0) 0.57(0.18–1.82) 0.999  
FGFR2 rs2981582      0.343
  C/C 11(37.9) 31(50.8) Reference   
  C/T 15(51.7) 21(34.4) 2.01(0.78–5.23) 0.151  
  T/T 3(10.3) 9(14.8) 0.94(0.22–4.11) 0.934  
  Dominat model 18(62.1) 30(49.2) 1.69(0.69–4.17) 0.254  
  Recessive model 26(89.7) 52(85.2) 1.50(0.37–6. 02) 0.567  
  Alleles      
  C 37(63.8) 83(68.0) Reference   
  T 21(36.2) 39(32.0) 1.21(0.63–2.33) 0.573  
  rs1219648      0.700
  A/A 9(31.0) 19(31.1) Reference   
  A/G 16(55.2) 30(49.2) 1.13(0.42–3.06) 0.816  
  G/G 4(13.8) 12(19.7) 0.70(0.18–2.80) 0.618  
  Dominat model 20(69.0) 42(68.9) 1.01(0.39–2.61) 0.99  
  Recessive model 25(86.2) 49(80.3) 1.53(0.45–5.24) 0.498  
  Alleles      
  A 34(58.6) 68(55.7) Reference   
  G 24(41.4) 54(44.3) 0.89(0.47–1.67) 0.715  
  rs2420946      0.377
  T/T 1(3.4) 11(18.0) Reference   
  C/T 18(62.1) 29(47.5) 6.83(0.81–57.45) 0.077  
  C/C 10(34.5) 21(34.4) 5.24(0.59–46.40) 0.137  
  Dominat model 28(96.6) 50(82.0) 6.16(0.76–50.24) 0.090  
  Recessive model 22(75.9) 54(88.5) 1.00 (0.39–2.53) 0.996  
  Alleles      
  T 20(34.5) 51(41.8) Reference   
  C 38(65.5) 71(58.2) 1.37(0.71–2.61) 0.348  
  rs2981579      0.060
  T/T 7(24.1) 18(29.5) Reference   
  C/T 12(41.4) 24(39.3) 1.29(0.42–3.92) 0.659  
  C/C 10(34.5) 19(31.1) 1.35(0.42–4.32) 0.610  
  Dominat model 22(75.9) 43(70.5) 2.39(0.96–5.99) 0.062  
  Recessive model 26(89.7) 51() 0.86(0.34–2.20) 0.752  
  Alleles      
  T 26(44.8) 60(49.2) Reference   
  C 32(55.2) 62(50.8) 1.19(0.64–2.23) 0.585  
  rs2981578      0.060
  G/G 10(34.5) 34(55.7) Reference   
  A/G 12(41.4) 20(32.8) 2.04(0.75–5.57) 0.164  
  A/A 7(24.1) 7(11.5) 3.40(0.96–12.02) 0.058  
  Dominat model 19(65.5) 27(44.3) 2.39(0.96–5.99) 0.062  
  Recessive model 22(75.9) 54(88.5) 0.41(0.13–1.30) 0.129  
  Alleles      
  G 32(55.2) 88(72.1) Reference   
  A 26(44.8) 34(27.9) 2.10(1.10–4.03) 0.025*  
FGFR3 rs743682      0.198
  G/G 25(86.2) 49(80.3) Reference   
  A/G 3(10.3) 11(18.0) 0.54(0.14–2.09) 0.368  
  A/A 1(3.4) 1(1.6) 1.96(0.12–32.67) 0.639  
  Dominat model 4(13.8) 12(19.7) 0.65(0.65–0.19) 0.498  
  Recessive model 27(93.1) 61(100) 0.47(0.03–7.74) 0.595  
  Alleles      
  G 53(91.4) 109(89.3) Reference   
  A 5(8.6) 13(10.7) 0.79(0.27–2.34) 0.671  
FGFR4 rs1966265      0.343
  G/G 8(27.6) 12(19.7) Reference   
  A/G 18(62.1) 22(36.1) 1.23(0.41–3.65) 0.713  
  A/A 3(10.3) 27(44.3) 0.17(0.04–0.74) 0.019*  
  Dominat model 21(72.4) 49(80.3) 1.16(0.64–1.80) 0.401  
  Recessive model 26(89.7) 34(55.7) 6.88(1.88–25.2) 0.004*  
  Alleles      
  G 34(58.6) 46(37.7) Reference   
  A 24(41.4) 76(62.3) 0.43(0.23–0.81) 0.009*  
  1. OR odds ratio, 95% CI 95% confidence interval, * A P value < 0.05 was considered ststistically significant